IMJUDO and IMFINZI usage in HCC (Hepatocellular Carcinoma) and BTC (Biliary Tract Cancer) Updates
This is an in-service training for staff of CUHK Medical Centre
Upon completion of the activity, participants will learn:
- New efficacy data from the Key Study in HCC: HIMALAYA Study
- New efficacy data from the Key Study in BTC: TOPAZ-1 Study
- Place in therapy for tremelimumab (IMJUDO) and durvalumab (IMFINZI)
Administration & Schedules for IMJUDO and IMFINZI
Date:
2024-08-26
Time:
1:15pm to 1:45pm
Venue:
L3 Pharmacy Service, CUHK Medical Centre, 9 Chak Cheung Street, Shatin
Organising Institute:
CUHK Medical Centre
Speaker:
Justin Li
Brand Manager, AstraZeneca Hong Kong Limited
HK Registered Pharmacist
Bachelor of Pharmacy (CUHK), Master of Business Administration (HKU) – undergoing
Related CPE Activities:
